Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of patients with HCC treated with TACE

From: Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma

Baseline characteristic n = 98, (%) or median, (range)
Age, years 71 (33–84)
Gender
 Male 76 (78)
 Female 22 (25)
Risk factors for Chronic Liver Disease
 Hepatitis C Virus infection 32 (33)
 Hepatitis B Virus Infection 12 (12)
 Ethanol Excess 38 (39)
 Others 9 (9)
 Unknown 8 (8)
Child Turcotte Pugh Class
 A 76 (77)
 B 22 (23)
BCLC Stage
 A 10 (10)
 B 77 (78)
 C 11 (11)
Number of Nodules
 1–2 77 (79)
 > 2 21 (21)
Maximum tumour diameter
 ≤ 7 cm 71 (72)
 > 7 cm 27 (28)
Portal vein invasion (PVI)
 Absent 87 (89)
 Present 11 (11)
Albumin, g/L 33 (14–47)
Total bilirubin, umol/L 17 (4–124)
ALT, IU/L 44 (10–348)
AST, IU/L 59 (20–999)
ALP, IU/L 207 (62–680)
AFP, ng/ml 45 (2–130.000)
INR 1.1 (1.0–1.4)
Platelet Count, ×  109/L 133 (46–444)
Number of TACE procedures
 1 33 (34)
 2 33 (34)
 ≥ 3 32 (32)
Prior Treatments
 First line TACE 78 (79)
 Resection 7 (6)
 Transplantation 1 (1)
 Radiofrequency ablation 22 (14)
Modified RECIST response following TACE
 Complete Response 15 (15)
 Partial Response 28 (29)
 Stable Disease 36 (37)
 Progressive Disease 7 (7)
 Missing 12 (12)
Peri-tumoural capsule (PTC)
 Absent 81 (83)
 Present 17 (17)
Ectatic arterial neovascularization (EAN)
 Absent 10 (10)
 Present 88 (88)
Artero-venous shunting (AVS)
 Absent 47 (48)
 Present 48 (49)
 Not assessable 3 (3)
Intra-tumour necrosis (ITN)
  < 50% 89 (90)
  > 50% 9 (10)